APA Style

al, R, N, E. (). Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials . : .

MLA Style

al, Ruperto, N,, Et. "Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials". : , . THERAPEUTIC CLASS.